Secondary hyperaldosteronism

Also known as: Secondary aldosteronism (disorder) / Secondary aldosteronism / Aldosteronism secondary

Drug	Drug Name	Drug Description
DB09015	Canrenoic acid	An aldosterone antagonist used in primary hyperaldosteronism and other disorders related to aberrant aldosterone levels.
DB00421	Spironolactone	An aldosterone receptor antagonist used to treat edema, hypertension, heart failure, and aldosteronism.

Drug	Drug Name	Target	Type
DB00421	Spironolactone	Mineralocorticoid receptor	target
DB00421	Spironolactone	Cytochrome P450 2C8	enzyme
DB00421	Spironolactone	Canalicular multispecific organic anion transporter 1	transporter
DB00421	Spironolactone	P-glycoprotein 1	transporter
DB00421	Spironolactone	Solute carrier organic anion transporter family member 1A2	transporter
DB00421	Spironolactone	Cytochrome P450 11B1, mitochondrial	enzyme
DB00421	Spironolactone	Androgen receptor	target
DB00421	Spironolactone	Progesterone receptor	target
DB00421	Spironolactone	Glucocorticoid receptor	target
DB00421	Spironolactone	Nuclear receptor subfamily 1 group I member 2	target
DB00421	Spironolactone	Bile salt export pump	transporter
DB00421	Spironolactone	Serum albumin	carrier
DB00421	Spironolactone	alpha1-acid glycoprotein	carrier
DB00421	Spironolactone	Estrogen receptor	target
DB00421	Spironolactone	Cytochrome P450 11B2, mitochondrial	enzyme
DB00421	Spironolactone	Voltage-dependent L-type calcium channel	target

Drug	Drug Name	Phase	Status	Count